Abbott Laboratories (NYSE:ABT) Receives $118.17 Average Price Target from Brokerages

Shares of Abbott Laboratories (NYSE:ABT) have earned a consensus recommendation of “Moderate Buy” from the twenty-seven research firms that are presently covering the company, MarketBeat reports. Four analysts have rated the stock with a hold rating, twenty have given a buy rating and three have issued a strong buy rating on the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $118.6667.

Several research firms have recently commented on ABT. Piper Sandler reissued an “overweight” rating and set a $118.00 target price (up from $115.00) on shares of Abbott Laboratories in a research report on Friday, July 17th. Weiss Ratings upgraded Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, August 6th. JPMorgan Chase & Co. boosted their price objective on Abbott Laboratories from $110.00 to $120.00 and gave the stock an “overweight” rating in a report on Friday, July 17th. Robert W. Baird started coverage on Abbott Laboratories in a research note on Wednesday, July 1st. They issued an “outperform” rating and a $121.00 price objective for the company. Finally, The Goldman Sachs Group cut their target price on Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating on the stock in a research report on Wednesday, May 27th.

Institutional Trading of Abbott Laboratories

Several institutional investors and hedge funds have recently made changes to their positions in the company. MidAtlantic Capital Management Inc. bought a new position in shares of Abbott Laboratories during the 4th quarter worth approximately $25,000. Cornerstone Financial Management LLC bought a new position in shares of Abbott Laboratories in the fourth quarter valued at approximately $25,000. Purpose Unlimited Inc. purchased a new stake in shares of Abbott Laboratories during the fourth quarter valued at approximately $25,000. Portfolio Resources Advisor Group Inc. bought a new stake in Abbott Laboratories during the fourth quarter worth $26,000. Finally, Abound Financial LLC purchased a new position in Abbott Laboratories in the fourth quarter worth $26,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Stock Performance

NYSE ABT opened at $112.92 on Wednesday. The company has a market cap of $195.39 billion, a P/E ratio of 36.54, a PEG ratio of 2.15 and a beta of 0.59. The company has a fifty day simple moving average of $98.51 and a 200 day simple moving average of $99.84. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $137.49.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The firm had revenue of $12.59 billion for the quarter, compared to the consensus estimate of $12.52 billion. During the same quarter in the prior year, the company posted $1.26 earnings per share. The business’s revenue was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Sell-side analysts predict that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th were paid a dividend of $0.63 per share. The ex-dividend date was Wednesday, July 15th. This represents a $2.52 annualized dividend and a yield of 2.2%. Abbott Laboratories’s dividend payout ratio (DPR) is 81.55%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.